Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 12.12.2019 | 12:50

Aladdin Healthcare Technologies SE: Announces it has co-published a scientific paper on AI to target Ageing


DGAP-Media / 12.12.2019 / 12:50

Aladdin Healthcare Technologies SE Announces
it has co-published a scientific paper on AI to target Ageing

 

(BERLIN, Germany and LONDON, England) 12 December 2019, Aladdin Healthcare Technologies SE ("Aladdin"), a leading developer of next generation breakthroughs in age-related disease accelerated by the integration of leading science and AI today announced it has co-published a scientific paper, in the 'Mechanisms of Ageing and Development' journal within Science Direct by Elsevier.

The paper titled, 'The NAD+-mitophagy axis in healthy longevity and in artificial intelligence-based clinical applications', delves into the concept that NAD+ could hold the key to early diagnosis and delay of neurodegenerative diseases. The paper focuses on 3 key points:

- Summarizing the importance of NAD+ and mitophagy in healthy longevity.

- Proposing an NAD+-mitophagy axis in health and disease, especially in neurodegenerative diseases.

- Discuss the importance and how to use artificial intelligence (AI) in the NAD+-mitophagy axis-based mechanistic studies, drug development.

Advances in our understanding of the molecular and cellular roles of NAD+ in mitophagy will lead to novel approaches for facilitating healthy mitochondrial homoeostasis that may serve as a promising therapeutic strategy to counter ageing-associated pathologies and/or accelerated ageing.

The paper shows that by collaborating with academic and medical partners Aladdin is changing the approach to early diagnosis of age-related disease using our AI capability. This forms the foundation for innovation into new products within this market.

Please follow this link to access the full paper: https://www.sciencedirect.com/science/article/abs/pii/S004763741930199X


Wade Menpes-Smith (Chairman)
 

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.



End of Media Release


Issuer: Aladdin Healthcare Technologies SE
Key word(s): Health

12.12.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.

News im Fokus

Deutsche Wohnen SE: Deutsche Wohnen schärft Bestandsprofil und setzt weitere Impulse für Neubau und Klimaschutz in Deutschland

13. August 2020, 06:56

Aktueller Webcast

home24 SE

Webcast Q2 Results 2020

14. August 2020

Aktuelle Research-Studie

Schweizer Electronic AG

Original-Research: Schweizer Electronic AG (von Montega AG): Halten

12. August 2020